Omniox is a biopharmaceutical company developing new medicines for hypoxic diseases. Hypoxia, defined as insufficient levels of oxygen in tissues, is known to trigger or impact a range of serious illnesses and conditions including many cancers, cardiovascular diseases, and trauma. At the center of Omniox’ work is a protein-based platform technology (H-NOX), that is engineered to reverse hypoxic disease states by delivering oxygen or nitric oxide preferentially to hypoxic tissues.

Korea Institute of Radiological & Medical Sciences specializes in radiation technology, research, development, genomics, and radiotherapy.

NH TherAguix SAS operates as a biotechnology company. The firm develops a nanodrug against cancer called AGuIX based on nanometric structuring that allows intravenous injection and the combination of the following properties to fight tumors: targeting, imaging, and treating. The company was founded by G��raldine Le Duc, Olivier Tillement and Fran��ois Lux in on December 11, 2015 and is headquartered in Meylan, France.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing therapies for life threatening diseases using its alpha particle immunotherapy platform and other related technologies. The company’s principal product candidates include Actimab-A, a Phase I/II clinical trial monoclonal antibody for the treatment of acute myeloid leukemia in elderly patients; and Iomab-B that has completed a Phase I/II design trial used to condition the bone marrow of patients by destroying blood cancer cells in their bone marrow. It also offers BC8-Y-90 and BC8-SA product candidates, which are in physician sponsored clinical phase I trials at the Fred Hutchinson Cancer Research Center. The company was founded in 2000 and is based in New York, New York.

Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company. The clinical stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used.

Shuttle Pharmaceuticals is a clinical-stage pharmaceutical company utilizing proprietary technology to develop novel therapies. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy. While there are several therapies being developed with the goal of curing cancer, one of the most effective and proven approaches to this is radiation therapy (RT).

Pola Chemical Industry, Inc. provides cosmetic products, chemicals doranidazole, and pola cosmetics. The company is headquartered in Shinagawa-Ku, Japan.

Cephalon is a global biopharmaceutical company dedicated to discovering, developing and bringing to market medications to improve the quality of life of individuals around the world. Since its inception in 1987, Cephalon has brought first-in-class and best-in-class medicines to patients in several therapeutic areas. Cephalon has the distinction of being one of the world's fastest-growing biopharmaceutical companies, now among the Fortune 1000 and a member of the S&P 500 Index, employing approximately 4,000 people worldwide. The company sells numerous branded and generic products around the world. In total, Cephalon sells more than 150 products in nearly 100 countries.

DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE.

Hospices Civils de Lyon provides health care services. It operates facilities including various predominantly general facilities that offers emergency, medical and surgical services in a wide range of disciplines, specialist facilities and four geriatric facilities. The company is headquartered in Lyon, France.

Kochi University offers the "Kochi University App" for smartphones to make students.

MSD Italia Srl, part of Merck & Co., Inc., is an Italian company located in Rome. The firm manufactures pharmaceutical products. It was founded in 1891. Nicoletta Luppi is the current CEO, occupying that position since 2003.

Trustees of Dartmouth College, part of Dartmouth College, is a company headquartered in Hanover, NH. The firm operates higher education institutes. It was founded in 1769.

Transgenex Nanobiotech, Inc. operates as a biotechnology company which engages in the discovery and development of nanoparticle formulations and nano-encapsulation methods for the treatment of acute and chronic lung diseases and cancers. It focuses on the development and marketing of diagnostic reagents/kits for the early detection of cancers and viral infections. The company was founded by Subhra Mohapatra and Shyam Mohaptra in 2004 and is headquartered in Lutz, FL.

Operates as an investment holding company

VBL Therapeutics is an innovative and diversified, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases. Currently available therapies are limited in their ability to adequately treat these serious and oftentimes life-threatening diseases. VBL was founded to create new treatment options that address these unmet medical needs. VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program.

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.